News sentiment analysis powered by sentiment-insight.com
Biocon Biologicals’ IPO only after integrating Viatris: CEO | Mint
Biocon Biologics acquired Viatris’ global biosimilar portfolio for $3.34 billion in November 2022. The company is also looking to secure US regulatory approval for Aspart (insulin biosimilar) and Bevacizumab.
Viatris core profit beats on generic drugs strength Viatris was formed through the merger of Mylan and Pfizer Inc's off-patent branded drugs business. The company's revenue fell about 3% to $3.94 billion for the quarter ended Sept. 30.
IQuest Enterprises acquires Viatris’ Indian API operations iQuest Enterprises has entered into a definitive agreement to acquire the API operations of global pharmaceutical major Viatris in India. The said operations include a total of six large scale API manufacturing facilities, three each in Vizag and Hyderabad, a R&D facility in Hyderabad as also third-party API sales.
Viatris $1.2 bn divestment sees it sell Indian API, women’s healthcare units Viatris said it was selling its API business in India involving six manufacturing sites, an R&D lab and third party API sales to investment firm IQuest Enterprises. Also divesting its women’s healthcare business, which includes two manufacturing facilities in India, to Spanish multinational Insud Pharma. Both transactions were expected to close in Q1 2024.
IQuest Enterprises acquires Viatris’ Indian API operations | Mint IQuest Enterprises to acquire API business of Viatris in India. This acquisition will also mark the return of Nimmagadda Prasad to the pharma industry after a 17-year hiatus.
Reuters Health News Summary Fresenius to assess whether state aid impacts bonus, dividend payouts. Cigna Group announces settlement with US on claims it overcharged Medicare Advantage. Drugmaker Viatris to divest some of its businesses.
IQuest Enterprises acquires Viatris’ Indian API operations | Mint IQuest Enterprises, a multi-sector investment company, Monday said it has entered into a definitive agreement to acquire the API (active pharmaceutical ingredient) operations of global pharmaceutical major Viatris in India. The said operations include a total of six large scale API manufacturing facilities.
Viatris $1.2 bn divestment sees it sell Indian API, women’s healthcare units Viatris said it was selling its API business in India involving six manufacturing sites, an R&D lab and third party API sales to investment firm IQuest Enterprises. It also divested its women’s healthcare business, which includes two manufacturing facilities in India, to Spanish multinational Insud Pharma. Both transactions were expected to close in Q1 2024.
Drugmaker Viatris to divest some of its businesses Viatris will divest its API business in India to an Indian pharmaceutical company, Iquest Enterprises. The company also received an offer for the divestiture of its Over-the-Counter (OTC) business.
Drugmaker Viatris to divest some of its businesses Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses. The company's move to divest some of its businesses is part of its efforts to streamline its focus on three core therapeutic areas.
Biocon to close Viatris merger by FY24 end | Mint Biocon closed its $3.34 billion acquisition of the global biosimilar portfolio of Viatris in November 2022. It paid $2 billion in cash, which included a $1.2 billion sustainability loan. In early June, the company said it had completed a third of the integration.
Biocon to close Viatris merger by FY24 end | Mint Biocon closed its $3.34 billion acquisition of the global biosimilar portfolio of Viatris in November 2022 in a cash and equity deal. It paid $2 billion in cash, which included a $1.2 billion sustainability loan. In early June, the company said it had completed a third of the integration, covering 70 emerging economies.
Viatris defeats IRS appeal in clash over legal fees in patent cases IRS argued Viatris owed $50 million for legal fees. Circuit court says legal fees from generic-drug patent cases are deductible.
‘Biocon Biologics ahead of plan in integrating Viatris’ | Mint Biocon Biologics has achieved a third of its post-deal integration with Viatris’s global biosimilar portfolio. The company expects to focus on integrating its US and European operations in the next phase.
MPP signs supply pact with Aurobindo Pharma, Cipla and Viatris for HIV drug | Mint The Medicines Patent Pool (MPP), United Nations-backed public health organisation, on Thursday announced that it has signed sublicensing agreements with pharmaceutical companies. Aurobindo Pharma, Cipla, and Viatris, for the manufacturing of generic variants of ViiV Healthcare's long-acting medication for HIV prevention. Through the MPP-ViiV healthcare agreement, these manufacturers will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP.
Aurobindo, Cipla, Viatris to make generic of ViiV’s HIV prevention drug The United Nations-backed public health organisation Medicines Patent Pool has signed sublicense agreements with Aurobindo Pharma, Cipla and Viatris. The drugmakers will manufacture generic versions of ViiV Healthcare’s long-acting HIV prevention medicine cabotegravir LA.
Aurobindo, Cipla, Viatris to make generic of ViiV’s HIV prevention drug The United Nations-backed public health organisation Medicines Patent Pool has signed sublicense agreements with Aurobindo Pharma, Cipla and Viatris (through its subsidiary Mylan) The drugmakers will manufacture generic versions of ViiV Healthcare’s long-acting HIV prevention medicine cabotegravir LA.
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later Viatris stock trades at less than 4 times its future earnings. Its dividend boasts an attractive yield of 4.1% at the current share price. You may want to consider adding this underrated stock to your portfolio.
Biocon Gets Rs 1070 Cr Boost From Kotak Special Situations Fund Kotak Special Situations Fund (KSSF), managed by Kotak Investment Advisors Limited (KIAL), announced an investment of Rs 1,070 crore in Biocon Limited (BL) Biocon will use the proceeds to finance Biocon Biologics’ acquisition of the biosimilars business of its partner Viatris. Biocon shares ended 2.25 per cent lower on the NSE at Rs 222.05 apiece.
Sign Up
